These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 10484767)

  • 1. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.
    Geneste O; Bidaud C; De Vita G; Hofstra RM; Tartare-Deckert S; Buys CH; Lenoir GM; Santoro M; Billaud M
    Hum Mol Genet; 1999 Oct; 8(11):1989-99. PubMed ID: 10484767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
    Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.
    Pelet A; Geneste O; Edery P; Pasini A; Chappuis S; Atti T; Munnich A; Lenoir G; Lyonnet S; Billaud M
    J Clin Invest; 1998 Mar; 101(6):1415-23. PubMed ID: 9502784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grb2 binding to the different isoforms of Ret tyrosine kinase.
    Alberti L; Borrello MG; Ghizzoni S; Torriti F; Rizzetti MG; Pierotti MA
    Oncogene; 1998 Sep; 17(9):1079-87. PubMed ID: 9764818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
    Melillo RM; Santoro M; Ong SH; Billaud M; Fusco A; Hadari YR; Schlessinger J; Lax I
    Mol Cell Biol; 2001 Jul; 21(13):4177-87. PubMed ID: 11390647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.
    Besset V; Scott RP; Ibáñez CF
    J Biol Chem; 2000 Dec; 275(50):39159-66. PubMed ID: 10995764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient.
    Angrist M; Bolk S; Halushka M; Lapchak PA; Chakravarti A
    Nat Genet; 1996 Nov; 14(3):341-4. PubMed ID: 8896568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
    Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
    Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
    Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein.
    Mercalli E; Ghizzoni S; Arighi E; Alberti L; Sangregorio R; Radice MT; Gishizky ML; Pierotti MA; Borrello MG
    Oncogene; 2001 Jun; 20(27):3475-85. PubMed ID: 11429694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor.
    Hayashi H; Ichihara M; Iwashita T; Murakami H; Shimono Y; Kawai K; Kurokawa K; Murakumo Y; Imai T; Funahashi H; Nakao A; Takahashi M
    Oncogene; 2000 Sep; 19(39):4469-75. PubMed ID: 11002419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
    Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
    Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline mutations of the RET ligand GDNF are not sufficient to cause Hirschsprung disease.
    Salomon R; Attié T; Pelet A; Bidaud C; Eng C; Amiel J; Sarnacki S; Goulet O; Ricour C; Nihoul-Fékété C; Munnich A; Lyonnet S
    Nat Genet; 1996 Nov; 14(3):345-7. PubMed ID: 8896569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational analysis of RET/GDNF/NTN genes in children with total colonic aganglionosis with small bowel involvement.
    Inoue K; Shimotake T; Iwai N
    Am J Med Genet; 2000 Aug; 93(4):278-84. PubMed ID: 10946353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function?
    Takahashi M; Iwashita T; Santoro M; Lyonnet S; Lenoir GM; Billaud M
    Hum Mutat; 1999; 13(4):331-6. PubMed ID: 10220148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A homozygous missense mutation in the tyrosine E kinase domain of the RET proto-oncogene in an infant with total intestinal aganglionosis.
    Shimotake T; Go S; Inoue K; Tomiyama H; Iwai N
    Am J Gastroenterol; 2001 Apr; 96(4):1286-91. PubMed ID: 11316186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial form of hirschsprung disease: nucleotide sequence studies reveal point mutations in the RET proto-oncogene in two of six families but not in other candidate genes.
    Munnes M; Fanaei S; Schmitz B; Muiznieks I; Holschneider AM; Doerfler W
    Am J Med Genet; 2000 Sep; 94(1):19-27. PubMed ID: 10982477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mutations of RET proto-oncogene in Hirschsprung disease].
    Lyonnet S; Edery P; Mulligan LM; Pelet A; Dow E; Abel L; Holder S; Nihoul-Fékéte C; Ponder BA; Munnich A
    C R Acad Sci III; 1994 Apr; 317(4):358-62. PubMed ID: 8000915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret.
    Melillo RM; Carlomagno F; De Vita G; Formisano P; Vecchio G; Fusco A; Billaud M; Santoro M
    Oncogene; 2001 Jan; 20(2):209-18. PubMed ID: 11313948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of amino acids surrounding tyrosine 1062 in ret in specific binding of the shc phosphotyrosine-binding domain.
    Ishiguro Y; Iwashita T; Murakami H; Asai N; Iida K; Goto H; Hayakawa T; Takahashi M
    Endocrinology; 1999 Sep; 140(9):3992-8. PubMed ID: 10465268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.